术后高分离性IMRT与每周一次西斯替代剂治疗头癌:IIa期试验
Shinya Hiraoka1, Aya Nakajima1, Masahiro Kikuchi2
1Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan.
Journal of radiation research
|March 5, 2025
概括
使用高分离强度调节放射疗法 (HF-IMRT) 的术后化疗放射治疗对于头部和部状细胞癌 (HNSCC) 患者是可行的. 这种方法可以安全地提供足够的西斯剂量和放射治疗,改善治疗结果.
科学领域:
- 在瘤学瘤学.
- 辐射疗法 辐射疗法
- 头部和部癌症 头部和部癌症
背景情况:
- 手术后化学放射疗法 (POCRT) 是高风险头支状细胞癌 (HNSCC) 的标准治疗方法.
- 强度调节放射治疗 (HF-IMRT) 中的高分离可能会改善POCRT的结果,但其可行性尚未被证明.
研究的目的:
- 评估使用HF-IMRT在具有高风险特征的HNSCC患者中POCRT的可行性.
- 评估这种综合方法的治疗完成率和安全概况.
主要方法:
- 潜在的可行性研究包括HNSCC患者的积极边缘或外节外延后手术.
- 治疗涉及HF-IMRT (73.6 Gy分成64个分量),每周服用西斯 (40 mg/m2).
- 可行性定义为治疗完成率>60% (放射治疗和≥200 mg/m2西斯).
主要成果:
- 九名患者完成了这项研究;中位数随访时间为18.2个月.
- 治疗完成率为88.9%,中位数的西斯普拉丁剂量为240 mg/m2.
- 77.8%的人经历了3级急性非血液学不良事件;没有发生4级+急性或3级+晚期不良事件.
结论:
- POCRT与HF-IMRT是HNSCC患者的可行和安全的治疗选择.
- 这种方法允许适当的西斯普拉丁剂量和放射治疗与可管理的毒性.
更多相关视频
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...